ISSN 0975-3583
 

Journal of Cardiovascular Disease Research



    Empagliflozin Reduces Body Weight And Indices of Adipose Distribution In Patients With Type 2 Diabetes Mellitus


    Dr Bharat Kumar Gupta
    JCDR. 2023: 1797-1802

    Abstract

    The escalating prevalence of diabetes has triggered a global health crisis, leading to substantial mortality, increased medical costs, and reduced quality of life. In 2021 alone, diabetes claimed 6.7 million lives worldwide and affected 537 million individuals, a number projected to surge to 643 million by 2030. India, with 74.9 million diabetic patients, ranks second worldwide, poised to reach 124.9 million by 2045. Obesity, a pivotal risk factor for type 2 diabetes (T2DM), accounts for 90% of cases. Visceral adipose tissue (VAT), linked to insulin resistance, plays a vital role in obesity-related T2DM development. Despite advancements, many risk factors remain inadequately managed. Sodium-glucose cotransporter (SGLT2) inhibitors have emerged as a novel class of anti-diabetic drugs, effectively lowering blood glucose and weight.

    Description

    » PDF

    Volume & Issue

    Volume 14 Issue 8

    Keywords